Positive Media Coverage Somewhat Unlikely to Affect Pacira Pharmaceuticals (PCRX) Share Price
Media stories about Pacira Pharmaceuticals (NASDAQ:PCRX) have trended positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.1549944341903 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- Short Interest in Pacira Pharmaceuticals, Inc. (PCRX) Increases By 53.8% (americanbankingnews.com)
- Steven Cohen Plunges Into Opioid Replacement Maker Pacira (finance.yahoo.com)
- Pacira Pharmaceuticals, Inc. (PCRX) Director Paul J. Hastings Sells 1,044 Shares (americanbankingnews.com)
- BRIEF-Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals (reuters.com)
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 0.14% on Wednesday, reaching $36.70. 137,516 shares of the company were exchanged. The stock’s market capitalization is $1.48 billion. The company has a 50-day moving average price of $41.49 and a 200 day moving average price of $45.06. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.21 earnings per share. On average, analysts forecast that Pacira Pharmaceuticals will post ($0.16) EPS for the current fiscal year.
A number of brokerages recently weighed in on PCRX. Royal Bank Of Canada set a $58.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Canaccord Genuity restated a “buy” rating and issued a $60.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, July 14th. Wedbush restated an “outperform” rating and issued a $87.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 19th. Finally, Zacks Investment Research cut shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.31.
In other news, SVP Scott Braunstein sold 768 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $43.32, for a total transaction of $33,269.76. Following the sale, the senior vice president now directly owns 9,982 shares in the company, valued at $432,420.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,913 shares of company stock worth $1,628,016. 6.60% of the stock is currently owned by company insiders.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.